Detalhe da pesquisa
1.
A unified framework for weighted parametric group sequential design.
Biom J
; 64(7): 1219-1239, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35704510
2.
On the empirical choice of the time window for restricted mean survival time.
Biometrics
; 76(4): 1157-1166, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32061098
3.
Stepwise two-stage sample size adaptation.
Stat Med
; 34(1): 27-38, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25252082
4.
On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
J Biopharm Stat
; 22(4): 617-40, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22651105
5.
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
JAMA Oncol
; 8(9): 1294-1300, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862037
6.
Multiplicity for a group sequential trial with biomarker subpopulations.
Contemp Clin Trials
; 101: 106249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338648
7.
Fitting spending functions.
Stat Med
; 29(3): 321-7, 2010 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19842091
8.
The MaxCombo Test Severely Violates the Type I Error Rate-Reply.
JAMA Oncol
; 9(4): 572, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36757709
9.
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Clin Cancer Res
; 24(23): 5841-5849, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29891725
10.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Clin Cancer Res
; 24(20): 4960-4967, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29685882
11.
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios".
Stat Biopharm Res
; 12(4): 520-521, 2020 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34191985
12.
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Clin Cancer Res
; 24(23): 6098, 2018 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510087
13.
The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.
Cancer Discov
; 1(1): 17-20, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22586314
14.
Finding the right dose for cancer therapeutics--can we do better?
Clin Cancer Res
; 16(4): 1085-7, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20145182
15.
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Am J Cardiol
; 90(6): 628-30, 2002 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12231090
16.
Optimal spending functions for asymmetric group sequential designs.
Biom J
; 49(3): 337-45, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17623339
17.
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
J Natl Cancer Inst
; 99(18): 1366-74, 2007 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17848668